drugset
drugset / Trial / NCT05761431

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

NCT05761431 ↗

Phase 1 Completed 56 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single-centre, single-dose, dose-escalation, placebo and positive drug-controlled Phase I clinical study in healthy Chinese subjects to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of octreotide injection in healthy Chinese subjects.

Timeline

Start
2023-03-02
Primary completion
2023-06-28
Completion
2023-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 0.1 mg Subcutaneous
Subject Octreotide Peptide 5 mg Subcutaneous
Subject Octreotide Peptide 10 mg Subcutaneous
Subject Octreotide Peptide 20 mg Subcutaneous
Subject Octreotide Peptide 20 mg Intramuscular
Subject Octreotide Peptide 30 mg Subcutaneous

Indications

acromegaly